Patents by Inventor Michael Kaleko

Michael Kaleko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
    Patent number: 10046035
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: August 14, 2018
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Michael Kaleko, Sheila Connelly, Vincent John Wacher
  • CARBAPENEMASES FOR USE WITH ANTIBIOTICS FOR THE PROTECTION OF THE INTESTINAL MICROBIOME
    Publication number: 20180221461
    Abstract: This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Application
    Filed: January 9, 2018
    Publication date: August 9, 2018
    Inventors: Michael KALEKO, Sheila CONNELLY
  • Beta-lactamases with improved properties for therapy
    Patent number: 10011824
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: July 3, 2018
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Michael Kaleko, Sheila Connelly
  • E. COLI-BASED PRODUCTION OF BETA-LACTAMASE
    Publication number: 20180030458
    Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.
    Type: Application
    Filed: August 27, 2015
    Publication date: February 1, 2018
    Inventors: Andrew BRISTOL, Michael KALEKO
  • BETA-LACTAMASES WITH IMPROVED PROPERTIES FOR THERAPY
    Publication number: 20180023072
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Application
    Filed: August 10, 2017
    Publication date: January 25, 2018
    Inventors: Michael Kaleko, Sheila Connelly
  • METHOD AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS
    Publication number: 20170368155
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Application
    Filed: July 5, 2017
    Publication date: December 28, 2017
    Inventors: Michael Kaleko, Sheila Connelly, Vincent John Wacher
  • BETA-LACTAMASES WITH IMPROVED PROPERTIES FOR THERAPY
    Publication number: 20170314006
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Application
    Filed: June 2, 2017
    Publication date: November 2, 2017
    Inventors: Michael Kaleko, Sheila Connelly
  • Beta-lactamases with improved properties for therapy
    Patent number: 9783797
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: October 10, 2017
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Michael Kaleko, Sheila Connelly
  • Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
    Patent number: 9744221
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 29, 2017
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Michael Kaleko, Sheila Connelly, Vincent John Wacher
  • Beta-lactamases with improved properties for therapy
    Patent number: 9695409
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: July 4, 2017
    Assignee: Synthetic Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • Complement Factor B Analogs and Their Uses
    Publication number: 20170037391
    Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 9, 2017
    Inventors: ChangHung CHEN, Michael KALEKO, Beibei LI, Tianci LUO, Jeffrey Allan MILLER, Ruigong WANG
  • Complement factor B analogs and their uses
    Patent number: 9533028
    Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 3, 2017
    Assignee: Wellstat ImmunoTherapeutics, LLC
    Inventors: ChangHung Chen, Michael Kaleko, Beibei Li, Tianci Luo, Jeffrey Allan Miller, Ruigong Wang
  • BETA-LACTAMASES WITH IMPROVED PROPERTIES FOR THERAPY
    Publication number: 20160362674
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Application
    Filed: August 24, 2016
    Publication date: December 15, 2016
    Inventors: Michael Kaleko, Sheila Connelly
  • BETA-LACTAMASES WITH IMPROVED PROPERTIES FOR THERAPY
    Publication number: 20160303207
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Application
    Filed: July 1, 2016
    Publication date: October 20, 2016
    Inventors: Michael Kaleko, Sheila Connelly
  • Beta-lactamases with improved properties for therapy
    Patent number: 9464280
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: October 11, 2016
    Assignee: Synthetic Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • CARBAPENEMASES FOR USE WITH ANTIBIOTICS FOR THE PROTECTION OF THE INTESTINAL MICROBIOME
    Publication number: 20160250304
    Abstract: This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Application
    Filed: February 23, 2016
    Publication date: September 1, 2016
    Inventors: Michael Kaleko, Sheila Connelly
  • Beta-lactamases with improved properties for therapy
    Patent number: 9404103
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: August 2, 2016
    Assignee: Synthetic Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • METHOD AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS
    Publication number: 20160193307
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Application
    Filed: December 23, 2015
    Publication date: July 7, 2016
    Inventors: Michael Kaleko, Sheila Connelly, Vincent John Wacher
  • Beta-lactamases with improved properties for therapy
    Patent number: 9376673
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: June 28, 2016
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Michael Kaleko, Sheila Connelly
  • BETA-LACTAMASE FORMULATIONS AND USES THEREOF
    Publication number: 20160101058
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Application
    Filed: October 8, 2015
    Publication date: April 14, 2016
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly